Efficacy and Prognostic Analysis of Erlotinib in Combination with Anlotinib or Bevacizumab Monoclonal Antibody in the Treatment of EGFR-sensitive Mutant Advanced NSCLC
LI Xia, LU Husheng, LIU Tan, et al
901 Hospital of the Chinese People's Liberation Army Joint Security Force, Anhui Hefei 230031, China
Abstract:Objective: To explore the efficacy and prognosis of erlotinib in combination with anlotinib or bevacizumab monoclonal antibody in the treatment of epidermal growth factor receptor (EGFR)-sensitive mutant advanced non-small cell lung cancer (NSCLC). Methods: A retrospective analysis was conducted on 107 patients with EGFR-sensitive mutant advanced NSCLC from September 2019 to February 2021, divided into Group A (55 cases) and Group B (52 cases). Group A received erlotinib + anlotinib, while Group B received erlotinib + bevacizumab. Short-term efficacy was assessed after one treatment cycle. Tumor markers, adverse reactions, and a 2-year follow-up were observed. Results: The objective response rate in Groups A and B was 58.18% and 63.46%, respectively, and the disease control rate was 89.09% and 90.38%, with no significant difference between the two groups (P>0.05). The differences in serum CA125, CEA, TPA, TK1, SCC-Ag, and CYFRA21-1 before and after treatment were not statistically significant (P>0.05). There was no significant difference in the incidence of adverse reactions between Groups A and B (P>0.05). The median progression-free survival in Groups A and B was 17.3 months and 18.1 months, respectively, with no statistically significant difference between the two groups (P>0.05). Conclusion: The efficacy and safety of erlotinib in combination with anlotinib or bevacizumab monoclonal antibody in the treatment of EGFR-sensitive mutant advanced NSCLC are comparable.
李侠, 卢虎生, 刘坦, 孙雪竹, 刘文静. 埃克替尼联合安罗替尼或贝伐珠单抗治疗表皮生长因子受体敏感突变晚期非小细胞肺癌的效果及预后分析[J]. 河北医学, 2023, 29(12): 2083-2087.
LI Xia, LU Husheng, LIU Tan, et al. Efficacy and Prognostic Analysis of Erlotinib in Combination with Anlotinib or Bevacizumab Monoclonal Antibody in the Treatment of EGFR-sensitive Mutant Advanced NSCLC. HeBei Med, 2023, 29(12): 2083-2087.